Compare Incyte Corporation (INCY) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Incyte Corporation trades at $120.55 (market cap $24.48B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $29.65. The key difference: Incyte Corporation is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| INCY | KOLD | |
|---|---|---|
Market Cap | $24.48B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $49.39 |
52-Week Low | $81.66 | $13.58 |
Enterprise Value | $19.98B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.52, down 0.45% on the day but maintains strong momentum with a 23% gain year-to-date in 2026. The stock shows bullish technical signals with moving averages supporting upward trends, while recent Q2 2026 earnings beat expectations with EPS of $3.09 versus $2.15 estimate. Revenue growth continues with 2025 reaching $5.14B and projected 2026 revenue of $5.8B, supported by strong product sales including Jakafi and Opzelura.
Outlook remains positive with analyst consensus price target of $122.82 representing 1.9% upside potential. Key opportunities include continued revenue growth and recent EU approval for Opzelura, while risks involve competitive pressures and the stock's proximity to 52-week highs. The company's strong profitability metrics with 27.71% net margin and 30.67% ROE support fundamental strength.
KOLD, trading at $28.54, declined 1.38% over the past 24 hours amid mixed technical signals, with a bullish overall trend from moving averages but neutral oscillators. Recent news highlights natural gas market volatility driven by weather forecasts and LNG demand, with the stock showing support near $28. The absence of fundamental ratios like P/E and P/S limits traditional valuation assessment, positioning it as a tactical play on energy sector movements.
The outlook for KOLD hinges on natural gas price swings, offering speculative opportunities from weather-driven demand shifts, but risks include production fluctuations and geopolitical impacts. Investors face elevated volatility without clear earnings metrics, requiring close monitoring of energy market dynamics for short-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
